Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Medulloblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Piperazine × CNS × Clear all
NCT02644291 2022-06-23

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
16 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡